



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Stem Cells

ESPS manuscript NO: 12940

Title: Stem cell therapy for retinal diseases

Reviewer code: 02439786

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-29 17:58

Date reviewed: 2014-07-30 10:18

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is well written manuscript and I recommended for publication. The manuscript have sufficient details about target disease of stem cells in Opnthalmology field and describes well about current situation stem cell therapy in this field . The writing is acceptable.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Stem Cells

ESPS manuscript NO: 12940

Title: Stem cell therapy for retinal diseases

Reviewer code: 00608332

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-29 17:58

Date reviewed: 2014-08-09 01:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The authors review the present strategies in retinal therapies based on stem cell strategies. This subject has been reviewed recently by Ng et al World J Stem Cells (2014) 6(2):111-9, although the present review is focused on retinal degeneration, and therefore is timely. The review is clear and well written, although some aspects of the format could be improved. It would be interesting to include tables summarizing the therapeutic strategies discussed and the clinical trials. In key words, the authors should use "Stargardt's disease" instead of only "Stargardt's". When more than one reference is listed together, the authors should put them under the same brackets i.e. (1,2) instead of (1)(2). Page 5. Hemorrhagic. Page 6. Outer segment. Page 8. Phagocytosis. It would be interesting to include the ligands of MerTK in the retina (Mol Cell Neurosci. 2006 33:96-108; Neuron. 2012 76(6):1123-32). Page 11 induction of photoreceptor damage (or damage of the photoreceptors). Page 12 gestational. Page 13 rhodopsin instead of rhodopsinin. Page 14 promising instead of promissing. Page. 15 enhance not enhance. In the final conclusion of the review, it would be interesting to know the opinion of the authors on the closing of the NIH stem cell program, as it included clinical trials on retinal pathologies.